Gotham Asset Management LLC Lowers Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Gotham Asset Management LLC lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 37.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,922 shares of the life sciences company's stock after selling 16,019 shares during the period. Gotham Asset Management LLC's holdings in Illumina were worth $3,598,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Golden State Wealth Management LLC bought a new stake in shares of Illumina during the fourth quarter worth about $32,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Illumina in the fourth quarter valued at $45,000. Assetmark Inc. increased its holdings in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares in the last quarter. Lee Danner & Bass Inc. bought a new position in shares of Illumina during the 4th quarter worth approximately $48,000. Finally, V Square Quantitative Management LLC increased its stake in shares of Illumina by 50.6% in the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company's stock valued at $52,000 after acquiring an additional 132 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Performance

NASDAQ ILMN traded up $1.62 on Tuesday, reaching $84.57. 660,248 shares of the company's stock traded hands, compared to its average volume of 2,310,753. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The firm has a market cap of $13.39 billion, a price-to-earnings ratio of -11.01, a P/E/G ratio of 1.60 and a beta of 1.35. The stock has a 50 day moving average price of $78.46 and a 200-day moving average price of $110.42.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.01. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same period in the previous year, the firm earned $0.98 EPS. The business's quarterly revenue was down 1.4% on a year-over-year basis. Equities research analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In related news, CFO Ankur Dhingra acquired 6,100 shares of Illumina stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the transaction, the chief financial officer now owns 24,906 shares in the company, valued at $2,022,616.26. This represents a 32.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 2.60% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. HSBC lowered shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 target price on the stock. in a research note on Friday, February 28th. JPMorgan Chase & Co. decreased their target price on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Morgan Stanley reduced their price objective on Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a research note on Monday, May 12th. Piper Sandler cut their price target on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. Finally, Canaccord Genuity Group lowered their target price on shares of Illumina from $92.00 to $87.00 and set a "hold" rating for the company in a report on Monday, May 12th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Illumina presently has a consensus rating of "Moderate Buy" and an average price target of $128.15.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.